Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor

Clinical and Experimental Immunology

Volumn 169, Issue 3, 2012, Pages 311-319

  Suttle, M M ^a   Nilsson, G ^c   Snellman, E ^b   Harvima, I T ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

IL 33; IL 6; IL 6 receptor; Mast cell; Psoriasis

Indexed keywords

INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TRYPTASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MAST CELL; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS SEVERITY INDEX; SKIN BIOPSY; SKIN CELL;

ADULT; AGED; BIOPSY; CELL COUNT; DERMIS; EPIDERMIS; ERYTHEMA; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKINS; MALE; MAST CELLS; MIDDLE AGED; PSORIASIS; RANDOM ALLOCATION; RECEPTORS, INTERLEUKIN-6; SEVERITY OF ILLNESS INDEX; SURGICAL TAPE; TIME FACTORS;

EID: 84864747363     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04618.x     Document Type: Article

References (45)

1. Harvima IT, Nilsson G, Suttle M-M, Naukkarinen A. Is there a role for mast cells in psoriasis? Arch Dermatol Res 2008; 300:461-78.
2. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005; 6:135-42.
3. Henz BM, Maurer M, Lippert U, Worm M, Babina M. Mast cells as initiators of immunity and host defense. Exp Dermatol 2001; 10:1-10.
4. Harvima IT, Naukkarinen A, Paukkonen K etal. Mast cell tryptase and chymase in developing and mature psoriatic lesions. Arch Dermatol Res 1993; 285:184-92.
5. Diaconu N-C, Kaminska R, Naukkarinen A, Harvima RJ, Harvima IT. The increase in tryptase- and chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma. J Eur Acad Dermatol Venereol 2007; 21:908-15.
6. Schubert C, Christophers E. Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res 1985; 277:352-8.
7. Brody I. Mast cell degranulation in the evolution of acute eruptive guttate psoriasis vulgaris. J Invest Dermatol 1985; 82:460-4.
8. Petersen LJ, Hansen U, Kristensen JK, Nielsen H, Skov PS, Nielsen HJ. Studies on mast cells and histamine release in psoriasis: the effect of ranitidine. Acta Derm Venereol (Stockh) 1998; 78:190-3.
9. Ackermann L, Harvima IT, Pelkonen J etal. Mast cells in psoriatic skin are strongly positive for interferon-gamma. Br J Dermatol 1999; 140:624-33.
10. Fischer M, Harvima IT, Carvalho RFS etal. Mast cell CD30 ligand is up-regulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest 2006; 116:2748-56.
11. Huttunen M, Naukkarinen A, Horsmanheimo M, Harvima IT. Transient production of stem cell factor in dermal cells but increasing expression of Kit receptor in mast cells during normal wound healing. Arch Dermatol Res 2002; 294:324-30.
12. Carvalho RFS, Nilsson G, Harvima IT. Increased mast cell expression of PAR-2 in skin inflammatory diseases and release of IL-8 upon PAR-2 activation. Exp Dermatol 2010; 19:117-22.
13. Ackermann L, Harvima IT. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-α and their degranulation is associated with expression of ICAM-1 in epidermis. Arch Dermatol Res 1998; 290:353-9.
14. Naukkarinen A, Järvikallio A, Lakkakorpi J, Harvima IT, Harvima RJ, Horsmanheimo M. Quantitative histochemical analysis of mast cells and sensory nerves in psoriatic skin. J Pathol 1996; 180:200-5.
15. Moussion C, Ortega N, Girard J. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS ONE 2008; 3:e3331.
16. Theoharides TC, Zhang B, Kempuraj D etal. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 2010; 107:4448-53.
17. Iikura M, Suto H, Kajiwara N etal. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007; 87:971-8.
18. Enoksson M, Lyberg K, Möller-Westerberg C, Falon PG, Nilsson G, Lunderius-Andersson C. Mast cells as sensors of cell injury through IL-33 recognition. J Immunol 2011; 186:2523-8.
19. Sabat R, Philipp S, Höflich C etal. Immunopathogenesis of psoriasis. Exp Dermatol 2007; 16:779-98.
20. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993; 101:701-5.
21. Lowes MA, Kikuchi T, Fuentes-Duculan J etal. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 cells. J Invest Dermatol 2008; 128:1207-11.
22. H17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445:648-51.
23. Ma HL, Liang S, Li J etal. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008; 118:597-607.
24. Chen Z, Laurence A, O'Shea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol 2007; 19:400-8.
25. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009; 129:1339-50.
26. H17 cells. Nature 2008; 454:350-2.
27. high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005; 174:164-73.
28. Sayed BA, Brown MA. Mast cells as modulators of T-cell responses. Immunol Rev 2007; 217:53-64.
29. Nilsson G, Svensson V, Nilsson K. Constitutive and inducible cytokine mRNA expression in the human mast cell line HMC-1. Scand J Immunol 1995; 42:76-81.
30. Lorentz A Schwengberg S, Sellge G, Manns MP, Bischoff SC. Human intestinal mast cells are capable of producing different cytokine profiles: role of IgE receptor cross-linking and IL-4. J Immunol 2000; 164:43-8.
31. Krüger-Krasagakes S, Möller A, Kolde G, Lippert U, Weber M, Henz BM. Production of interleukin-6 by human mast cells and basophilic cells. J Invest Dermatol 1996; 106:75-9.
32. 1. Clin Exp Allergy 1999; 29:105-13.
33. Mizutani H, Schechter NM, Lazarus GS, Black RA, Kupper TS. Rapid and specific conversion of precursor interleukin 1β (IL-1β) to an active IL-1 species by human mast cell chymase. J Exp Med 1991; 174:821-5.
34. Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-β1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 1995; 270:4689-96.
35. Zhao W, Oskeritzian CA, Pozez AL, Schwartz LB. Cytokine production by skin-derived mast cells: endogenous proteases are responsible for degradation of cytokines. J Immunol 2005; 175:2635-42.
36. Harvima IT, Haapanen L, Ackermann L, Naukkarinen A, Harvima RJ, Horsmanheimo M. Decreased chymase activity is associated with increased levels of protease inhibitors in mast cells of psoriatic lesions. Acta Derm Venereol (Stockh) 1999; 79:98-104.
37. Grossman RM, Krueger J, Yourish D etal. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989; 86:6367-71.
38. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009; 183:3170-6.
39. Farber EM, Nall ML. The natural history of psoriasis in 5600 patients. Dermatologica 1974; 148:1-18.
40. Toruniowa B, Jablonska S. Mast cells in the initial stages of psoriasis. Arch Dermatol Res 1988; 280:189-93.
41. Diaconu N-C, Kaminska R, Naukkarinen A, Harvima RJ, Nilsson G, Harvima IT. Increase in CD30 ligand/CD153 and TNF-α expressing mast cells in basal cell carcinoma. Cancer Immunol Immunother 2007; 56:1407-15.
42. Kandere-Grzybowska K, Kempuraj D, Cao J, Cetrulo CL, Theoharides TC. Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin. Br J Pharmacol 2006; 148:208-15.
43. Castellani ML, Perrella A, Kempuraj DJ etal. Immunological activation of human umbilical cord blood mast cells induces tryptase secretion and interleukin-6, and histidine decarboxylase mRNA gene expression. Pharmacol Res 2007; 55:57-63.
44. Rivera J. Adaptors discriminate mast-cell cytokine production from eicosanoid production and degranulation. Trends Immunol 2006; 27:251-3.
45. + cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 2011; 187:4598-610.